Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlituo plus FOLFOX versus Erbitux plus FOLFOX as first-line treatment for RAS/BRAF wild-type, MSS/pMMR advanced or metastatic colorectal cancer
CTR20261822Phase 3Active
- Sponsor
- Mabpharm Limited
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in colorectal cancer (CRC), sponsored by Mabpharm Limited. Started Jun 2026; status: active.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20261822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261822.